The molecular diagnostics startup GNA Biosolutions has closed a $13.5 million Series C financing round, attracting new investors including Greybird Ventures, Occident, and Wachstumsfonds Bayern.
But also well-known financiers such as SHS Gesellschaft für Beteiligungsmanagement, Robert Bosch Venture Capital, UVC Partners, Mey Capital Matrix, KfW and Btov Partners are back on board.
"Rapid molecular diagnostics are key to patient care in an increasingly broad range of therapeutic areas, particularly in infectious diseases. We believe that PCA technology will overcome many limitations of existing molecular diagnostics and enable rapid treatment decisions that improve patient care."
says Tom Miller, Partner at Greybird Ventures, the lead investor in the financing round.
These are the next steps
The new investment is planned by the molecular diagnostics startup GNA Biosolutions for the further development of PCA technology (Pulsed Control Amplification) The technology can amplify nucleic acids directly from samples such as whole blood, sputum, and nasal swabs. The company also aims to obtain CE-IVD marking for its point-of-care molecular diagnostics platform. To achieve this, in vitro diagnostics (IVDs) must comply with certain guidelines. GNA Biosolutions plans to launch the platform first in Europe and later in the US. It has already been used in several tests to detect infectious diseases and biothreats.
“This Series C financing will help us implement our regulatory strategy and bring PCA into the clinic,”
commented Federico Buersgens, Co-founder and Managing Director of GNA Biosolutions.
